Home / Publications / Tripeptide Phe-Trp-Leu-NH2 as a putative endogenous ligand of TSPO: molecular modeling, synthesis and pharmacological activity

Tripeptide Phe-Trp-Leu-NH2 as a putative endogenous ligand of TSPO: molecular modeling, synthesis and pharmacological activity

Olga Alekseevna Deeva 1
Olga Alekseevna Deeva
, 
Andrey Sergeevich Pantileev 1
Andrey Sergeevich Pantileev
, 
Oxana Yur'evna Kravtsova 1
Oxana Yur'evna Kravtsova
, 
Sergey Vladimirovich Nikolaev 1
Sergey Vladimirovich Nikolaev
, 
Nikolay Alekseevich Zefirov 2
Nikolay Alekseevich Zefirov
, 
Polina Yur'evna Povarnina 1
Polina Yur'evna Povarnina
, 
Tatiana Alekseevna Antipova 1
Tatiana Alekseevna Antipova
, 
Tatiana Alexandrovna Gudasheva 1
Tatiana Alexandrovna Gudasheva
, 
Vladimir L'vovich Dorofeev 1
Vladimir L'vovich Dorofeev
1 Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russian Federation
2 Department of Chemistry, M.V. Lomonosov Moscow State University, Moscow, Russian Federation
10.1016/j.mencom.2024.09.018
Published 2024-09-09
Communication , Volume 34, Issue 5, 682-684
0
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Deeva O. A. et al. Tripeptide Phe-Trp-Leu-NH2 as a putative endogenous ligand of TSPO: molecular modeling, synthesis and pharmacological activity // Mendeleev Communications. 2024. Vol. 34. No. 5. pp. 682-684.
GOST all authors (up to 50) Copy
Deeva O. A., Pantileev A. S., Kravtsova O. Y., Nikolaev S. V., Zefirov N. A., Povarnina P. Y., Antipova T. A., Gudasheva T. A., Dorofeev V. L. Tripeptide Phe-Trp-Leu-NH2 as a putative endogenous ligand of TSPO: molecular modeling, synthesis and pharmacological activity // Mendeleev Communications. 2024. Vol. 34. No. 5. pp. 682-684.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2024.09.018
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2024.09.018
TI - Tripeptide Phe-Trp-Leu-NH2 as a putative endogenous ligand of TSPO: molecular modeling, synthesis and pharmacological activity
T2 - Mendeleev Communications
AU - Deeva, Olga Alekseevna
AU - Pantileev, Andrey Sergeevich
AU - Kravtsova, Oxana Yur'evna
AU - Nikolaev, Sergey Vladimirovich
AU - Zefirov, Nikolay Alekseevich
AU - Povarnina, Polina Yur'evna
AU - Antipova, Tatiana Alekseevna
AU - Gudasheva, Tatiana Alexandrovna
AU - Dorofeev, Vladimir L'vovich
PY - 2024
DA - 2024/09/09
PB - Mendeleev Communications
SP - 682-684
IS - 5
VL - 34
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2024_Deeva,
author = {Olga Alekseevna Deeva and Andrey Sergeevich Pantileev and Oxana Yur'evna Kravtsova and Sergey Vladimirovich Nikolaev and Nikolay Alekseevich Zefirov and Polina Yur'evna Povarnina and Tatiana Alekseevna Antipova and Tatiana Alexandrovna Gudasheva and Vladimir L'vovich Dorofeev},
title = {Tripeptide Phe-Trp-Leu-NH2 as a putative endogenous ligand of TSPO: molecular modeling, synthesis and pharmacological activity},
journal = {Mendeleev Communications},
year = {2024},
volume = {34},
publisher = {Mendeleev Communications},
month = {Sep},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2024.09.018},
number = {5},
pages = {682--684},
doi = {10.1016/j.mencom.2024.09.018}
}
MLA
Cite this
MLA Copy
Deeva, Olga Alekseevna, et al. “Tripeptide Phe-Trp-Leu-NH2 as a putative endogenous ligand of TSPO: molecular modeling, synthesis and pharmacological activity.” Mendeleev Communications, vol. 34, no. 5, Sep. 2024, pp. 682-684. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2024.09.018.

Keywords

antidepressant-like activity
anxiolytic activity
neuroprotective activity.
tripeptide
TSPO ligand

Abstract

The putative endogenous tripeptide ligand of the translocator protein (TSPO) l-phenylalanyl-l-tryptophanyl-l-leucine amide was obtained using the drug-based peptide design strategy and molecular modeling. This tripeptide demonstrated anxiolytic activity in the elevated plus-maze test and antidepressant-like activity in the forced swimming test in BALB/c mice at the doses of 10 mg kg−1 (i.p.) and also showed neuroprotective activity in the concentration range of 10−5-10−7 m in vitro under conditions of oxidative stress using HT-22 neuronal cell line.

References

.
UCSF Chimera?A visualization system for exploratory research and analysis
Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E.
Journal of Computational Chemistry, 2004
.
GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers
Abraham M.J., Murtola T., Schulz R., Páll S., Smith J.C., Hess B., Lindahl E.
SoftwareX, 2015
.
CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields
Vanommeslaeghe K., Hatcher E., Acharya C., Kundu S., Zhong S., Shim J., Darian E., Guvench O., Lopes P., Vorobyov I., Mackerell A.D.
Journal of Computational Chemistry, 2009
.
Zefirov N.A., Glaßl A., Radchenko E.V., Borovik A.N., Stanishevskiy V.V., Milaeva E.R., Kuznetsov S.A., Zefirova O.N.
Mendeleev Communications, 2022
.
The New Dipeptide TSPO Ligands: Design, Synthesis and Structure–Anxiolytic Activity Relationship
Gudasheva T.A., Deeva O.A., Pantileev A.S., Mokrov G.V., Rybina I.V., Yarkova M.A., Seredenin S.B.
Molecules, 2020
.
Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations
Leader L.D., O'Connell M., VandenBerg A.
Pharmacotherapy, 2019
.
Structure of the Mitochondrial Translocator Protein in Complex with a Diagnostic Ligand
Jaremko Ł., Jaremko M., Giller K., Becker S., Zweckstetter M.
Science, 2014
.
Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders
Rupprecht R., Papadopoulos V., Rammes G., Baghai T.C., Fan J., Akula N., Groyer G., Adams D., Schumacher M.
Nature Reviews Drug Discovery, 2010
.
Nerve growth factor effects on pyridine nucleotides after oxidant injury of rat pheochromocytoma cells
Jackson G.R., Werrbach-Perez K., Ezell E.L., Post J.F., Regino Perez-Polo J.
Brain Research, 1992
.
Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand
Kita A., Kohayakawa H., Kinoshita T., Ochi Y., Nakamichi K., Kurumiya S., Furukawa K., Oka M.
British Journal of Pharmacology, 2004
.
The EROP-Moscow oligopeptide database
Zamyatnin A.A.
Nucleic Acids Research, 2006
.
Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs?
Schüle C., Eser D., Baghai T.C., Nothdurfter C., Kessler J.S., Rupprecht R.
Neuroscience, 2011
.
Synthesis and evaluation of novel potent TSPO PET ligands with 2-phenylpyrazolo[1,5-a]pyrimidin-3-yl acetamide
Hieu Tran V., Park H., Park J., Kwon Y., Kang S., Ho Jung J., Chang K., Chul Lee B., Lee S., Kang S., Kim H.
Bioorganic and Medicinal Chemistry, 2019
.
Translocator Protein as a Promising Target for Novel Anxiolytics
Costa B., Da Pozzo E., Martini C.
Current Topics in Medicinal Chemistry, 2012
.
Sedláček M., Kořínek M., Petrovič M., Cais O., Adamusová E., Chodounská H., Vyklický L.
Physiological Research, 2008
.
The Ligands of Translocator Protein: Design and Biological Properties
Mokrov G.V., Deeva O.A., Gudasheva T.A.
Current Pharmaceutical Design, 2020
.
Design, Synthesis and Anxiolytic Activity Evaluation of N-Acyltryptophanyl- Containing Dipeptides, Potential TSPO Ligands#
Gudasheva T.A., Deeva O.A., Mokrov G.V., Dyabina A.S., Yarkova M.A., Seredenin S.B.
Medicinal Chemistry, 2018
.
Novel Technologies for Dipeptide Drugs Design and their Implantation
Gudasheva T.A., Ostrovskaya R.U., Seredenin S.B.
Current Pharmaceutical Design, 2018
.
Erwin Schrödinger
Physics Today, 2015